The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients

International Angiology

Volumn 22, Issue 1, 2003, Pages 79-82

  Hatzaki, A ^a   Anagnostopoulou, E ^a   Metaxa Mariatou, V ^a   Melissinos, C ^a   Philalithis, P ^a   Iliadis, K ^a   Kontaxis, A ^a   Liberatos, K ^a   Pangratis, N ^a   Nasioulas, G ^a  

^a HYGEIA HOSPITAL   (Greece)

Author keywords

Factor V; Prothrombin; Risk factors; Thrombophilia, diagnosis; Thrombophilia, genetics

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; RESTRICTION ENDONUCLEASE; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; GREECE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATIENT REFERRAL; PHENOTYPE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RESTRICTION MAPPING; STATISTICAL MODEL; VEIN THROMBOSIS;

FACTOR V; FEMALE; GENE FREQUENCY; GREECE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTHROMBIN; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 0038048003     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-32.
2. Price DT, Ridker PM. Factor V Leiden and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127:895-903.
3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
4. Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 1997;98:907-9.
5. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
6. Majerus PW. Bad blood by mutation. Nature 1994;369: 14-5.
7. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
8. Chaida C, Gialeraki A, Tsoukala C, Mandalaki T. Prevalence of the FVQ506 mutation in the Hellenic population. Thromb Haemost 1996;76:127.
9. Antoniadi T, Hatzis T, Kroupis C, Economou-Petersen E, Petersen MB. Prevalence of factor V Leiden, prothrombin G20210A and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 1999;61:265-7.
10. Ioannou HV, Mitsis M, Eleftheriou A, Matsagas M, Nousias V, Rigopoulos C et al. The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece. Int Angiol 2000;19: 314-8.
11. Rosendaal FR, Doggen CMJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79:706-8.
12. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrïmbin gene. Blood 1998;92:1119-24.
13. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study group for pooled-analysis in venous thromboembolism. Thromb Haemost 2001;86:809-16.
14. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801-6.
15. Mitsis M, Ioannou H, Eleftheriou A, Nousias V, Basioukas V, Kakosimos G et al. Combined genetic defect (homogeneity for factor V Leiden and heterogeneity for prothrombin G20210A allele) in a young patient, with recurrent deep vein thrombosis and serious postphlebitic syndrome. Angiology 2000;51:325-9.
16. De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994;72: 880-6.
17. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH et al. The risk of recurrent venous thromboembolism in patients with an arg506-to-gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
18. Coen D, Zadro R, Honoviæ L, Banfliæ L, Stavljeniæ Rukavina A. Prevalence and association of the factor V Leiden and prothombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J 2001;42:488-92.
19. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342: 374-80.
20. Hatzis T, Cardamakis E, Drivalas E, Makatsoris K, Bevan D, Pantos C et al. Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagubility factors. Eur J Contracept Reprod Health Care 1999;4:135-44.